Gastrointestinal Cancers Symposium

GI 2017 Daily News - Thursday

Issue link:

Contents of this Issue


Page 0 of 27

Dr. Calvin Kuo to Deliver Keynote Lecture on Use of Organoids for Cancer Biology Research C ancer research has his- torically relied on the use of transformed cell lines to test if a candidate on- cogene alters characteristics in vitro. However, advances in the fi eld of organoids—or models of human tissue—are begin- ning to allow researchers to more clearly study the effects of cancer on the human body. Calvin Kuo, MD, PhD, the Maureen Lyles D'Ambrogio Professor at Stanford University School of Medicine and vice chair for basic and translation- al research in the Department of Medicine at Stanford, has focused much of his research career on studying the growth of normal tissues and tumor biopsy specimens as three- dimensional organoids for mod- eling cancer biology. His team's work has allowed the fi rst in vi- tro conversion of normal colon, stomach, and pancreatic tissues to adenocarcinoma. Dr. Kuo will discuss his research and the latest developments in the fi eld of organoids during his keynote lecture "The Journey From In- testinal Stem Cells to Cancer Organoids" (January 19, 10:00 AM-11:00 AM). Dr. Kuo received his medi- cal and postdoctoral degrees in cancer biology from Stan- ford University and trained in internal medicine at Brigham and Women's Hospital. He began focusing his career on adult oncology during his fel- lowship at Dana-Farber Cancer Institute. Dr. Kuo now runs the Calvin Kuo Laboratory at Stan- ford University and co-leads the Cancer Biology Program at the Stanford Cancer Center. A Growing Interest in Organoids Dr. Kuo's interest in organ- oids grew from his interest in intestinal stem cells. As a post- doctoral fellow, he started grow- ing intestines as organoids in his laboratory, and since then, he has expanded his work past studying stem cells in vivo and in vitro to studying organoids and modeling cancer in these "miniature organs." "Studying organoids poten- tially has many different ap- plications," Dr. Kuo said. "We think they are [a tool that enables the study of] cancer functional genomics, allowing validation of mutations or epi- genetic alterations in cancer— that is, what are driving events versus passenger events." In the current landscape, re- searchers have a tremendous scale of genome datasets from thousands of individual cancers that have been completely se- quenced and analyzed, leaving a large number of alterations that may or may not be causing cancer. Now the challenge fac- ing researchers is to try to func- tionally prove or disprove that these alterations do or do not cause cancer, Dr. Kuo said. Traditionally, cell lines have been used to test the role of genetic alterations in cancer in "top-down" modeling. Al- though the use of these cell lines has been a useful tool for discovery, many have large Colorectal Cancer Heterogeneity: Evolving Classifi cation Schemes for Prognostication and Prediction for Response to Therapy Kit Man Wong, MD, and William M. Grady, MD U sing whole genome sequencing, epigenetic analysis, and gene expression analysis to characterize colorectal cancer (CRC) has led to a greater understanding of this disease and has revealed its remarkable molecular heterogeneity. Al- though the TNM staging system for CRC established by the Ameri- can Joint Committee on Cancer is currently the standard classifi ca- tion approach used in clinical practice to determine prognosis, 1 a signifi cant variability in patient outcomes is observed within the same TNM stage. 2 This highlights the reality that other factors are relevant beyond the extent of disease in determining the prognosis of patients with CRC. It is widely believed that the most accurate CRC classifi cation system will include measures of the intrinsic bi- ology of the tumor to not only provide an accurate prognostic tool but also a predictive tool for response to specifi c targeted therapies. CRC has been previously subdivided at a molecular level in dif- ferent ways. Many of the existing classifi cation schemes are based on inherent tumor cell characteristics. However, with the increas- ing appreciation for the role that the tumor microenvironment and host immune system play in tumorigenesis, 3 these extrinsic factors have been integrated into recently proposed classifi cation systems. Tumor Cell–Based Molecular Profi ling The genome-wide assessment of recurrent somatic mutations in key oncogenes and tumor suppressors in CRC has been made possi- ble by recent advances in DNA sequencing technology. The Cancer Genome Atlas (TCGA) network conducted a comprehensive analy- sis of somatic alterations in more than 250 colorectal tumors, which revealed the most commonly mutated genes, including APC (81%), Attendee Tip of the Day The Attendee Resource Center is an all-in-one location for links to useful Symposium materials, including: ➤ Visit the Attendee Resource Center: See Keynote Lecture, Page 12 Emerging Treatment Options for Gastric Cancer Florian Lordick, MD, PhD G astric cancer (GC) is a global health problem. Approximately 1 mil- lion new GC cases occur every year, making it the fi fth most common malignancy in the world. GC is the third lead- ing cause of cancer death in both sexes worldwide (723,000 deaths, 8.8% of total cancer deaths). 1 Many patients present with locally advanced or meta- static disease, which mandates the use of systemic chemother- apy, either perioperatively or with palliative intent. HER2 and VEGFR2 are clini- cally validated molecular targets for the treatment of metastatic GC. Trastuzumab, a HER2-directed monoclonal antibody, and ramucirumab, a VEGFR2-directed antibody, are See Colorectal Cancer Heterogeneity, Page 3 T A R G E T I N G C A N C E R C A R E Trainee & Early-Career Networking Luncheon 4 Surgery After Neoadjuvant Chemotherapy in Advanced GC 5 Incorporating Radiation Oncology Into Immunotherapy 5 Role of Stereotactic Body Radiotherapy in the Management of HCC 16 Restaurant Recommendations 16 AGA Prepares Gastroenterologists for the New World of Reimbursement 17 CancerLinQ ® Platform Hits Patient Records Milestone 17 Symposium Essentials 17, 18, 21 70th Annual SSO Cancer Symposium 21 Ancillary Educational Events 21 Combination Strategies for Immunotherapy in GI Cancers 22 My Meeting Experience: A Surgeon's Perspective 23 Earning MOC Points at the 2017 GI Cancers Symposium 24 About the 2017 GI Cancers Symposium Cosponsors 25 Ergonomics and Endoscopic- Related Injuries in Gastroenterologists 25 INSIDE Dr. Calvin Kuo DAILY NEWS THURSDAY · JA N UA RY 1 9 · SA N F RA N C I S CO Gastrointestinal Cancers Symposium O 2017 • Abstracts • Find a Colleague directory • Virtual Meeting • CME Request See Emerging Treatment Options, Page 6

Articles in this issue

view archives of Gastrointestinal Cancers Symposium - GI 2017 Daily News - Thursday